CDK4 and neoplasm: CDK4/6 inhibitors are a novel class of selective cell cycle therapeutics that target the cyclin D-CDK4/6 complex and suppress activation of the downstream RB-E2F pathway, thereby blocking cell cycle progression and inhibiting the tumor cell proliferation [6–8].